Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
The complaint alleges the company has profited from research spearheaded by the CDC.
The pop star’s party is named after the HIV prevention drug and is meant as an homage to ’80s-era queer nightlife.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
Relying on Gilead’s payment assistance program to pay for Truvada delayed their first dose by an additional 16 days.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
How insidious is the reach of Big Pharma? It can affect our policy-making, and even trick people like me into shilling for them.
This finding held after researchers controlled for the proportion of people in medical care for HIV who had a fully suppressed viral load.
Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.
After identifying these priorities, Gilead Sciences launched its TRANScend Fund. Here’s how to apply for a grant.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Nationwide, significant proportions of PrEP-using populations do not stay on Truvada for long.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.